摘要
慢性阻塞性肺疾病所致肺动脉高压(COPD-PH)的发病率和病死率高,患者3年生存率仅为41%。目前COPD-PH的常规对症治疗以及针对PH的靶向治疗,效果均不理想。非编码RNAs作为重要的内源基因调节因子,严格调控生理和病理过程。COPD-PH患者中存在非编码RNAs表达的改变,且发现其在COPD-PH发病机制中发挥重要作用,故非编码RNA有望成为治疗COPD-PH的关键治疗靶点。本文就微小RNAs、环状RNAs和长链非编码RNAs等在COPD-PH缺氧、高炎症和氧化应激等病理过程中所起作用的有关研究进展进行综述。
The prevalence of morbidity and mortality of pulmonary hypertension caused by chronic obstructive pulmonary disease(COPD-PH)is high,and the three-year survival rate of these patients is only 41%.At present,the conventional symptomatic treatment for COPD-PH and the targeted treatment for PH are non-ideal.Noncoding RNAs,as important endogenous gene regulators,strictly regulate physiological and pathological processes.Many studies have indicated that the expression changes of noncoding RNAs are in patients with COPD-PH,which play an important role in the pathogenesis of COPD-PH.Therefore,noncoding RNA as promise become a key therapeutic target for COPD-PH.In this paper,the research progress on the role of micro RNAs(miRNAs),circular RNAs(circRNAs)and long noncoding RNAs(lncRNAs)in the pathological processes of COPD-PH,such as hypoxia,high inflammation and oxidative stress is reviewed.
作者
李娟
沈毅
何嘉豪
陈扬航
姚漪婷
杨佳诺
林小靖
莫展杰
刘春丽
Li Juan;Shen Yi;He Jiahao;Chen Yanghang;Yao Yiting;Yang Jianuo;Lin Xiaojing;Mo Zhanjie;Liu Chunli(Department of Respiratory and Critical Diseases,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510000,China)
出处
《国际呼吸杂志》
2022年第7期495-500,共6页
International Journal of Respiration
基金
呼吸疾病国家重点实验室自主课题(SKDRD-MS-201901)
广州医科大学高水平大学建设科研教学能力提升项目(B205001082)。
关键词
肺动脉高压
肺疾病
慢性阻塞性
非编码RNAS
Pulmonary hypertension
Pulmonary disease,chronic obstructive
Noncoding RNAs